Welcome to the e-CCO Library!

DOP033: Trends in epidemiology of Inflammatory Bowel Disease among Jewish Israeli adolescents: A population based study
Year: 2018
Source: ECCO'18 Vienna
Authors: Ghersin Itai
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP034: Assessment of direct healthcare cost drivers of Crohn’s disease in a Dutch population-based cohort study shows a major shift
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Lalisang1*, D. Wintjens1,2, M. Romberg-Camps3, A. van Bodegraven3, L. Oostenbrug3, J. Haans1, A. Masclee1,2, D. Jonkers1,2, M. Pierik1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP034: Assessment of direct healthcare cost drivers of Crohn's Disease in a Dutch population-based cohort study shows a major shift
Year: 2018
Source: ECCO'18 Vienna
Authors: Lalisang Robbert
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP034: Comparative effectiveness of infliximab and adalimumab in Crohns disease: results from a real-life population-based cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Jeuring*1, 2, D. Wintjens1, T. Van den Heuvel1, 2, M. Zeegers3, 4, 
W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1, 2, D. Jonkers1, 2, M. Pierik1, 2

Created: Friday, 22 February 2019, 9:49 AM
DOP034: Serum adalimumab concentration 3 months after surgery is correlated with endoscopic recurrence in Crohn's disease patients treated with adalimumab for prevention of postoperative recurrence
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Boivineau L.*1, Bourgaux J.F.2, Pineton de Chambrun G.1, Caillo L.2, Danan G.1, Boitard J.1, Liautard J.1, Guillon F.1, Altwegg R.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP035: Beclomethasone dipropionaat is effective for microscopic colitis: results of an open-label multicentre study (COLCO)
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. De Corte1, E. Janssens1*, K. Thorrez2, A. D'Hondt1, K. Dejaegher3, F. D'Heygere4, B. van Besien2, L. Harlet1, H. Peeters5, W. Vanmoerkercke4, P. van Hootegem6, F. Baert1

Created: Thursday, 21 February 2019, 9:14 AM
DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schoenefuss F., Hoffmann P.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBD
Year: 2017
Source: ECCO'17 Barcelona
Authors: Schoenefuss F.
Therapeutic drug monitoring, Anti-TNF agents, Adalimumab, Infliximab
Files: 1
DOP035: Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agents
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Molander*1, 2, M. Färkkilä2, 3, H. Kemppainen4, T. Blomster5, A. Jussila6, H. Mustonen7, T. Sipponen2, 3

Created: Friday, 22 February 2019, 9:49 AM
DOP035: Longterm outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agents
Year: 2016
Source: ECCO'16 DOP
Authors: Molander P.
Anti-TNF agents, real world data
Files: 1
DOP036: Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Fiorino*1, P. Ellul2, M. Muscat2, P. Karatzas3, M. Silva4, A. Peixoto4, C. Felice5, F. Bossa6, P.L. Lakatos7, S. Sebastian8, B. Ungar9, F. Furfaro1, K. Karmiris10, K.H. Katsanos11, P. Navarro Cortes12, M.M. Boscà Watts12, D.K. Christodoulou11, G. Maconi13, U. Kopylov9, A. Armuzzi5, F. Magro4, G. Mantzaris3, S. Ben-Horin9, S. Danese1, 14

Created: Friday, 22 February 2019, 9:49 AM
DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylation
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bloemendaal F.*1, Levin A.2, Wildenberg M.2, Koelink P.2, Visser R.3, Claassens J.4, Bradford M.5, D'Haens G.2, Verbeek S.4, Vidarsson G.3, van den Brink G.2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylation
Year: 2017
Source: ECCO'17 Barcelona
Authors: Bloemendaal F.
Anti-TNF agents, Immunology, Macrophage
Files: 1
DOP036: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study (ICC case series)
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Biemans1,2*, A. van der Meulen - de Jong3, C. van der Woude4, N. de Boer5, G. Dijkstra6, B. Oldenburg7, C. Ponsioen8, P. Maljaars3, J. Haans2, M. Pierik2, F. Hoentjen9, Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 21 February 2019, 9:14 AM
DOP036: Ustekinumab for Crohn's Disease: A nationwide real-life observational cohort study (ICC Case Series)
Year: 2018
Source: ECCO'18 Vienna
Authors: Biemans Vince
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP037: A model for prediction of early surgery and complications in paediatric Crohn's disease: results of the prospective GROWTH CD study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Levine A.*1,2, Hussey S.3, Kolho K.L.4, Sladek M.5, de Carpi J.M.6, Turner D.7, Russell R.K.8, Cohen-Dolev N.9, Escher J.10 Porto-ECCO GROWTH CD Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
DOP037: A model for prediction of early surgery and complications in paediatric Crohn’s Disease; Results of the prospective GROWTH CD study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Levine A.
paediatric, post operative complications, digestive tract damage
Files: 1